For patients who received a letter on improperly disclosed information by a claims processing vendor, read more.

Excellence is just the beginning.

Translate

French German Italian Portuguese Russian

Lymphoma Services — Clinical Trials

Cutaneous T-Cell Lymphoma Treatment Study

A phase 3 multicenter, randomized, placebo-controlled study to determine the effect of topical SGX301 and fluorescent bulb-light irradiation for the treatment of cutaneous T-cell lymphoma.

Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype Treatment Study

A randomized double-blind phase III study of ibrutinib during and following autologous stem cell transplantation versus placebo in patients with relapsed or refractory diffuse large B-cell lymphoma of the activated B-cell subtype.

Diffuse Large B-Cell Lymphoma Treatment Study

A phase 2 study of the combination of ublituximab + TGR-1202 and TG-1202 alone in patients with previously treated diffuse large B-cell lymphoma.

Follicular Lymphoma Treatment Study

Study of ibrutinib and rituximab in subjects whose follicular lymphoma has not been treated before.

Mantle Cell Lymphoma Treatment Study

Rituximab with or without stem cell transplant in mantle cell lymphoma.

Marginal Zone Lymphoma Treatment Study

A study of INCB050465 in subjects with relapsed or refractory marginal zone lymphoma.

MYC-Associated B-Cell Lymphomas Treatment Study

Prospective, multi-center phase I/II trial of lenalidomide and dose-adjusted EPOCH-R in MYC-associated B-cell lymphomas.

Newly Diagnosed Classical Hodgkin Lymphoma Treatment Study

A randomized phase 3 study of brentuximab vedotin (SGN-35, IND #117117) for newly diagnosed high-risk classical Hodgkin lymphoma (cHL) in children and young adults.

Relapsed or Refractory Follicular Lymphoma Treatment Study

Obinutuzumab with or without umbralisib, lenalidomide, or combination chemotherapy in treating patients with relapsed or refractory follicular lymphoma.

Relapsed or Refractory Mantle Cell Lymphoma Treatment Study

A phase 2, open-label, 2-cohort, multicenter study of INCB050465, a PI3Kδ inhibitor, in relapsed or refractory mantle cell lymphoma previously treated with or without a BTK inhibitor (CITADEL-205).

Pages